Tagged as: Certolizumab pegol

Biogen and Xbrane Enter into Worldwide Commercialization and License Agreement for Certolizumab Pegol Biosimilar

On February 7, 2022, Biogen Inc. and Xbrane Biopharma AB announced that they had entered into a commercialization and license agreement related to Xcimzane, a certolizumab pegol biosimilar referencing CIMZIA.  Under the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, and Xbrane will be responsible…

Read More